Please login to the form below

Not currently logged in
Email:
Password:

Novel muscle relaxant reverser wins US priority review status

The FDA assigns priority review status to US-based pharmaceutical company Schering-Plough's NDA for sugammadex

The FDA has assigned priority review status to US-based pharmaceutical company Schering-Plough's (S-P) New Drug Application (NDA) for sugammadex.

Sugammadex reverses the effects of US-marketed muscle relaxants, such as Zemuron (rocuronium) and vecuronium, which are used in general anaesthesia during surgical procedures.

If approved, sugammadex will be the first in a new class of drugs known as selective relaxant binding agents which encapsulate the muscle relaxant molecule and render it inactive.

S-P's CMO, Dr Robert Spiegel, said: "Sugammadex has the potential to change the way doctors practice anaesthesia as it will allow anaesthesiologists to rapidly and safely reverse both shallow and profound levels of muscle relaxation, which is not possible with current reversal agents."

S-P acquired sugammadex through its acquisition of Organon BioSciences on 19 November 2007.

3rd January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics